Business
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company
Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from
About this update from Biolife Solutions, Inc.
[{"type":"text","content":"Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology\nMarks the second acquisition from Bioproduction Innovation Accelerator program\nBOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) (\"BioLife\" or the \"Company\"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (\"CGT\") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., (\"PanTHERA\"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor (\"IRI\") technology. The acquisition further strengthens BioLife's position as the market leader in biopreservation, enhancing its product portfolio of consumable solutions and adds scientific capabilities to the management team.\n\n \n \n \n \n \n \n\n \nPanTHERA has completed the development and launched its first-generation IRI technology, while progressing development on its next generation molecules designed to be combined with BioLife's line of cryopreservation products. These next-generation formulations are expected to launch within 18 months and have the potential to provide superior cryopreservation outcomes for certain biological constructs, utilize lower concentrations of DMSO while maintaining cryopreservation efficacy, and reduce the need for liquid nitrogen used in cold chain logistics and long term storage. BioLife initially invested in PanTHERA in 2020 through its Bioproduction Innovation Accelerator, co-sponsored with Casdin Capital.\nRoderick de Greef, BioLife Chairman and CEO, commented, \"This acquisition is an extension of our strategy to strengthen BioLife's leadership position as a pure play consumables provider and enabler of advanced therapies. PanTHERA's differentiated IRI technology enhances our core capabilities in biopreservation, and their talented scientific team shares our commitment to deliver innovative, enabling solutions for the fast-growing CGT market.\"\nDr. Aby Mathew, BioLife Chief Scientific Officer, added, \"With the addition of PanTHERA's IRI technology and the expertise of Drs. Jason Acker and Robert Ben, we're deepening our scientific bench and extending our technological edge. Together we are advancing the next wave of cryopreservation solutions to support our...